"Immune effects of escalating doses of granulocyte-macrophage colony-stimulating factor added to a fixed, low-dose, inpatient interleukin-2 regimen: a randomized phase I trial in patients with metastatic melanoma and renal cell carcinoma." by John W. Smith

Selected Works of Walter J. Urba, MD, PhD

Article

Immune effects of escalating doses of granulocyte-macrophage colony-stimulating factor added to a fixed, low-dose, inpatient interleukin-2 regimen: a randomized phase I trial in patients with metastatic melanoma and renal cell carcinoma.

Journal of Immunotherapy (2003)

John W. Smith, Loyola University Chicago
Robert A. Kurt, Lafayette College
Angelo G. Baher, Providence Portland Medical Center
Susan Denman
Lisa Justice
Teri Doran, Providence Portland Medical Center
Mark Gilbert
W. Gregory Alvord, National Institutes of Health
Walter J. Urba, Providence Portland Medical Center

Link

Disciplines

Publication Date

January 3, 2003

DOI

10.1097/00002371-200303000-00005

Citation Information

John W. Smith, Robert A. Kurt, Angelo G. Baher, Susan Denman, et al.. "Immune effects of escalating doses of granulocyte-macrophage colony-stimulating factor added to a fixed, low-dose, inpatient interleukin-2 regimen: a randomized phase I trial in patients with metastatic melanoma and renal cell carcinoma." Journal of Immunotherapy Vol. 26 Iss. 2 (2003) p. 130 - 138
Available at: http://works.bepress.com/walter-urba/221/